Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Peptides vs Gastric Sleeve Non-Surgical Weight Loss: Full Comparison

Before selecting an intervention, understand what each requires. Not just what it promises. Mechanism Pharmacological appetite modulation via incretin receptor agonism. Slows gastric emptying, extends satiety hormone elevation Surgical anatomical restriction.

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • Before selecting an intervention, understand what each requires. Not just what it promises.
  • Mechanism
  • Pharmacological appetite modulation via incretin receptor agonism. Slows gastric emptying, extends satiety hormone elevation
  • Surgical anatomical restriction. Removes 75–80% of stomach, reduces ghrelin-producing fundus
  • Peptides are reversible and dose-dependent; sleeve is permanent structural change with forced compliance
  • Mean Weight Loss (12 months)
  • 15–22% total body weight (dose-dependent; higher with tirzepatide 15mg)
  • 25–30% total body weight
  • Sleeve produces slightly higher initial loss; peptides approach similar outcomes at maximum dose
  • Persistence After Stopping
  • ~67% of lost weight regained within 12 months of cessation (STEP-1 Extension)
  • Permanent anatomical restriction. Regain occurs via calorie-dense liquids, not volume increase
  • Peptides require indefinite use for sustained effect; sleeve restriction persists lifelong
  • Administration
  • Weekly subcutaneous self-injection; dose titration over 16–20 weeks to therapeutic level
  • One-time laparoscopic procedure under general anesthesia; 60–90 minute surgery
  • Peptides demand ongoing adherence; sleeve is one intervention with no further dosing
  • Cost (U.S., 2026)
  • $300–$1,200/month for compounded; $1,300–$1,500/month for branded (Wegovy, Mounjaro)
  • $15,000–$23,000 out-of-pocket; insurance covers if BMI ≥40 or ≥35 with comorbidity
  • Peptides are recurring monthly expense; sleeve is upfront capital cost
  • Adverse Events
  • GI side effects (nausea, vomiting, diarrhea) in 30–45% during titration; rare pancreatitis, gallbladder disease
  • 2–5% surgical complications (leak, stricture, bleeding); 0.1–0.2% mortality; dumping syndrome in 10–15%
  • Peptide side effects are temporary and dose-related; sleeve carries surgical and anesthesia risk

Related resources

More comparisons